China’s gene-editing jab offers new hope for 30 million thalassaemia carriers

China has developed a new therapy that uses gene editing to treat thalassaemia, the world’s most common genetic blood disorder. The country is home to 30 million carriers of the disease, while the global total reaches 350 million. Patients with severe thalassaemia face a stark reality: regular blood transfusions, potential organ transplants, and a risk of premature death. If two carriers marry, their children have a 25 percent chance of developing the disease. The new treatment, which integrates advanced gene editing techniques, marks a breakthrough in tackling the inherited condition. While details on clinical trial results remain limited, the therapy raises hope for millions who currently have few treatment options.